Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
For a 5 mg semaglutide vial, 0.5-1 mL of bacteriostatic water creates a concentrated solution appropriate for the tiny weekly doses
As an pro-angiogenic agent, it's theoretically possible for BPC-157 to enable cancers to grow
Combination-Protocol Research Beyond the individual studies referenced above, several published research lines have specifically investigated BPC-157 and TB-500 in combination : Combined BPC-157 + TB-500 in musculoskeletal injury models searches across rodent rotator-cuff, Achilles tendon and ligament transection research
